MagnaChip to Present at 2018 Needham Growth Conference
Get Alerts MX Hot Sheet
Join SI Premium – FREE
SEOUL, South Korea and SAN JOSE, Calif., Jan. 16, 2018 /PRNewswire/ -- MagnaChip Semiconductor Corporation ("MagnaChip") (NYSE: MX) today announced that members of the executive management team will make an investor presentation at the 2018 Annual Needham Growth Conference in New York City on Wednesday, January 17, 2018 at 1:30 p.m. EST. An audio webcast of the presentation can be heard here: http://wsw.com/webcast/needham84/mx/
The webcast link also can be accessed within the "Investors" section of the MagnaChip website, under the heading of "Investor Events." A replay of the webcast will be available one hour after the conclusion of the presentation and will be accessible on the MagnaChip website for 90 days.
About MagnaChip Semiconductor MagnaChip is a designer and manufacturer of analog and mixed-signal semiconductor platform solutions for communications, IoT, consumer, industrial and automotive applications. The Company's Standard Products Group and Foundry Services Groups provide a broad range of standard products and manufacturing services to customers worldwide. MagnaChip, with over 30 years of operating history, owns a portfolio of approximately 3,300 registered patents and pending applications, and has extensive engineering, design and manufacturing process expertise. For more information, please visit www.magnachip.com. Information on or accessible through, MagnaChip's website is not a part of, and is not incorporated into, this release.
|
CONTACTS: |
|
|
In the United States: Bruce Entin Investor Relations Tel. +1.408.625.1262
|
In Korea: Chankeun Park Director, Public Relations Tel. +82.2.6903.5223
|
View original content:http://www.prnewswire.com/news-releases/magnachip-to-present-at-2018-needham-growth-conference-300582880.html
SOURCE MagnaChip Semiconductor Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MagnaChip (MX) files $50M mixed shelf
- Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
- Ruvi AI (RUVI) Announces Phase 3 Has Reached 90% Sellout as Investors Race to Secure Remaining Tokens at $0.02
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share